Stay updated on Fostamatinib and Ruxolitinib in Myelofibrosis Clinical Trial
Sign up to get notified when there's something new on the Fostamatinib and Ruxolitinib in Myelofibrosis Clinical Trial page.

Latest updates to the Fostamatinib and Ruxolitinib in Myelofibrosis Clinical Trial page
- Check5 days agoNo Change Detected
- Check12 days agoChange DetectedRevision updated: added v3.5.0 and removed v3.4.3.SummaryDifference0.1%

- Check19 days agoNo Change Detected
- Check26 days agoChange DetectedPage revision updated from v3.4.2 to v3.4.3; core study details appear unchanged.SummaryDifference0.1%

- Check55 days agoChange DetectedAn updated site revision tag (v3.4.2) was added, and an existing government funding status notice (v3.4.1) was removed. The study’s content and data remain unchanged.SummaryDifference0.4%

- Check62 days agoChange DetectedA government funding notice and status update were added to the page footer. The site revision label was updated from v3.4.0 to v3.4.1.SummaryDifference0.4%

- Check69 days agoChange DetectedAdded a glossary toggle and updated metadata labels (Last Update Submitted that Met QC Criteria, No FEAR Act Data, and Revision: v3.4.0). Removed the older labels (Last Update Submitted that met QC Criteria, No FEAR Act data, and Revision: v3.3.4).SummaryDifference0.2%

- Check83 days agoChange DetectedThe page now displays Revision: v3.3.4, replacing the previous Revision: v3.3.3.SummaryDifference0.1%

Stay in the know with updates to Fostamatinib and Ruxolitinib in Myelofibrosis Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Fostamatinib and Ruxolitinib in Myelofibrosis Clinical Trial page.